Lipid biomarkers may reveal hidden kidney disease risk in type 1 diabetes
Lipid biomarkers may reveal hidden kidney disease risk in type 1 diabetes
Lipid biomarkers may reveal hidden kidney disease risk in type 1 diabetes
A new study has uncovered lipid biomarkers that could help detect kidney disease risk in people with early-stage type 1 diabetes. These markers may offer a way to spot trouble even when standard tests show normal kidney function. The findings come from an international team led by Dr Farsad Afshinnia, a nephrologist at University of Michigan Health.
The research involved over 800 patients with type 1 diabetes. Scientists compared those with rapid kidney decline to those with minimal loss of function. Historically, doctors have relied on estimated glomerular filtration rate and urine albumin tests to assess kidney health. But these methods often fail to predict problems in early-stage diabetes when kidneys appear healthy.
Earlier work by Afshinnia and Dr Subramaniam Pennathur had already shown that certain lipids influence kidney disease progression in type 2 diabetes. This time, the team suspected that lipid patterns might differ between type 1 and type 2 diabetes, affecting how kidneys deteriorate. Their analysis identified 47 lipids that varied significantly between patients with fast and slow kidney decline. The findings highlight key differences in how lipids predict diabetic kidney disease across diabetes types. While the tests show promise, their ability to forecast kidney problems in early-stage diabetes—when function is still normal—remains limited.
The study reveals potential new tools for early detection of kidney disease in type 1 diabetes. These lipid biomarkers could complement existing tests, though their predictive power has boundaries. Further research may determine how best to use them in clinical practice.